Ovarian cancer is poorly immunogenic; however, increased major histocompatibility complex class II (MHCII) expression correlates with improved immune response and prolonged survival in patients with ovarian cancer. The authors previously demonstrated that the histone deacetylase inhibitor entinostat increases MHCII expression on ovarian cancer cells. In the current study, they evaluated whether entinostat treatment and resultant MHCII expression would enhance beneficial immune responses and impair tumor growth in mice with ovarian cancer. METHODS: C57BL/6 mice bearing intraperitoneal ID8 tumors were randomized to receive entinostat 20 mg/kg daily versus control. Changes in messenger RNA (mRNA) expression of 46 genes important for antitumor immunity were evaluated using NanoString analysis, and multicolor flow cytometry was used to measure changes in protein expression and tumor-infiltrating immune cells. RESULTS: Entinostat treatment decreased the growth of both subcutaneously and omental ID8 tumors and prolonged survival in immunocompetent C57BL/6 mice. NanoString analysis revealed significant changes in mRNA expression in 21 of 46 genes, including increased expression of the MHCI pathway, the MHCII transactivator (CIITA), interferon γ, and granzyme B. C57BL/6 mice that received entinostat had increased MHCII expression on omental tumor cells and a higher frequency of tumor-infiltrating, CD8-positive T cells by flow cytometry. In immunocompromised mice, treatment with entinostat had no effect on tumor size and did not increase MHCII expression. CONCLUSIONS: In the current murine ovarian cancer model, entinostat treatment enhances beneficial immune responses. Moreover, these antitumor effects of entinostat are dependent on an intact immune system. Future studies combining entinostat with checkpoint inhibitors or other immunomodulatory agents may achieve more durable antitumor responses in patients with ovarian cancer. Cancer 2018;124:4657-4666.
INTRODUCTION
Although approximately 75% of patients with ovarian cancer will achieve clinical remission with a combination of surgery and taxane/platinum chemotherapy, the majority of patients will relapse and ultimately die of their disease. 1 The introduction of targeted therapies has done little to impact overall survival (OS) for women with ovarian cancer, and responses to immunotherapy have been disappointing, with overall response rates ≤15% with currently available checkpoint inhibitors. [2] [3] [4] [5] Epigenetic changes, which alter gene expression without modifying the underlying DNA sequence, play an important role in cancer pathogenesis. One of the most common epigenetic pathways involves acetylation of lysine residues on the amino-terminal tails of histone proteins. Histone acetyl transferases add negatively charged acetyl groups to neutralize histone charge and convert chromatin into a more transcriptionally permissive state, whereas histone deacetylases (HDACs) antagonize this process and lead to transcriptional repression and gene silencing. 6 Eighteen HDACs have been identified and divided into 4 classes based on sequence homology with yeast. 7 The class I HDACs are the most prevalent and are expressed at high levels in ovarian cancer, in which their expression has been correlated with the development of platinum resistance and decreased survival in patients. [8] [9] [10] Cancer December 15, 2018 Several HDAC inhibitors have received US Food and Drug Administration approval, all of which act by targeting the zinc ion required for catalytic action of the class I, II, and IV HDACs. 11 These agents can directly inhibit tumor growth by a variety of mechanisms, including cell cycle arrest, inhibition of angiogenesis, and promotion of apoptosis. 7 In addition, HDAC inhibitors can indirectly contribute to disease control by rendering tumor cells more immunogenic and upregulating antigen presentation pathways and costimulatory surface molecules. [12] [13] [14] [15] Our group and others previously demonstrated that entinostat, a class I specific benzamide HDAC inhibitor, leads to increased major histocompatibility complex II (MHCII) expression on ovarian cancer cells, 16 a phenotype that correlates with higher numbers of tumor-infiltrating lymphocytes and improved survival. [17] [18] [19] In the current study, we evaluated the effects of entinostat on the adaptive immune response in a syngeneic murine ovarian cancer model. We observed that entinostat treatment of ovarian tumor-bearing mice led to a reduction in tumor growth and prolonged survival. In whole tumor lysates, genes involved in antigen presentation, T-cell inhibition and exhaustion, and T-cell effector function were differentially expressed after entinostat treatment. These observations correlated with an increase in tumor-infiltrating, cluster of differentiation 8 (CD8)-positive T cells and were contingent on adaptive immunity.
MATERIALS AND METHODS

Cell Lines and Culture
The ID8 murine epithelial ovarian cancer cell line was provided by Dr. Yancey Gillespie (University of Alabama at Birmingham, Birmingham, AL). Cells were maintained in RPMI1640 (Mediatech, Inc., Manassas, VA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA). Cells were passaged by dissociation with 0.05% trypsin, 0.53mM ethylene diamine tetraacetic acid without sodium bicarbonate (Corning, Inc., Corning, NY), washing, and reculturing. Cells were maintained in culture less than 10 passages from the parent stock. Experiments were performed at 70% to 80% confluency.
Mouse Studies
All animal studies were approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee. Immunocompetent C57BL/6 mice were obtained from Charles River Laboratories International (Wilmington, MA). Recombination activating gene 1 (Rag1) knockout mice, which lack T and B lymphocytes, were obtained from The Jackson Laboratory (Bar Harbor, ME). Experiments were performed in mice at 7 or 8 weeks of age.
For subcutaneous tumor models, mice were injected in the right flank with 7 × 10 6 ID8 cells in a 1:1 mixture of phosphate-buffered saline (PBS) (Mediatech, Inc.) and growth-factor reduced Matrigel Matrix basement membrane (Discovery Labware, Inc., Billerica, MA). Mice were weighed weekly, and tumors were measured with calipers twice weekly in 2 dimensions (length × width). Treatment was started when the majority of mice in each group had tumors measuring at least 16 mm 2 , which took approximately 30 days after ID8 cell injection. For intraperitoneal tumor models, mice were injected intraperitoneally with 7 × 10 6 ID8 cells in 200 μL PBS. Treatment was started 28 days after injection.
Mice were randomized to 14 days of treatment with either entinostat 20 mg/kg (LC Laboratories, Woburn, MA) dissolved in 70% PBS, 20% Kolliphor EL (SigmaAldrich, St Louis, MO), and 10% dimethyl sulfoxide (Sigma-Aldrich) or with vehicle control. Treatments were administered by intraperitoneal injection. At the conclusion of the treatment period, mice were either killed or observed for survival analysis. Omental tumors were harvested for flow cytometry and NanoString analysis (NanoString, Inc., Seattle WA).
NanoString nCounter mRNA Analysis C57BL/6 mice were injected with ID8 cells intraperitoneally and treated with entinostat or vehicle control for 14 days as described above. Omental tumors were subsequently harvested, and mRNA was extracted using the TRIsol Plus RNA Purification Kit (Life Technologies Corporation, Carlsbad, CA). Five hundred microliters of TRIsol reagent was added to each tumor sample. Tumors were homogenized manually using a mortar and pestle and subsequently passaged 5 to 10 times through an 18-gauge syringe. The remainder of RNA extraction was performed according to manufacturer instructions. RNA quantification was performed using the DeNovix DS-11 Spectrophotometer (Denovix, Inc., Wilmington, DE). Samples were processed on the NanoString nCounter Flex System according to the manufacturer's instructions using a custom 46-gene immune panel designed based on the work of our group and others to interrogate genes involved in adaptive immunity (for a full list of genes, see Supporting Table 1 ). Expression levels were normalized to housekeeping genes. Analysis was performed
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Flow Cytometry
Omental tumors were fragmented with scissors and placed in 2 mL Iscove modification of Dulbecco modified eagle medium (Corning, Inc.) supplemented with 3.5% bovine serum albumin (Sigma, St. Louis, MO), 0.5 mg/mL collagenase (Sigma), and 70 μg/mL DNAse I. Tumor fragments were placed in an orbital shaker at 250 revolutions per minute for 30 minutes at 37°C and subsequently filtered through 70-μm nylon strainers (Corning, Inc.). The following antibodies were used for staining: programmed cell death 1 ligand 1 (PD-L1) (12-5982-83), CD3 (catalog no. 47-0032-82), forkhead box P3 (FoxP3) (catalog no. 25-5773-82), and CD45.2 (catalog no. 17-0454-82; all from eBioscience, San Diego, CA); CD8 (catalog no. 560776) and CD25 (catalog no. 557192; both from BD Biosciences, San Jose, CA); CD4 (catalog no. 560782; BD Horizon/BD Biosciences); I-A/I-E (catalog no. 107627; BioLegend, San Diego, CA); and LIVE/ DEAD red fixable dye (Life Technologies Corporation). Fixation and permeabilization were performed using the FoxP3/Transcription Factor Staining Buffer Set (eBioscience). Samples were run using a BDFACS Canto II (BD Biosciences). Data were analyzed with FlowJo software (version 9.9; FlowJo, LLC, Ashland, OR).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism (version 7.0;GraphPad Software, La Jolla, CA). Tumor areas, mean normalized gene expression, mean fluorescent intensity (MFI), and percentages of infiltrating immune cells were compared using independent 2-tailed t tests with α = .05. Survival analyses were performed using the Kaplan-Meier method, and curves were compared using the Mantel-Cox log-rank test.
RESULTS
Entinostat Inhibits Tumor Growth and Prolongs Survival in a Murine Ovarian Cancer Model
Several studies demonstrate diverse anticancer effects of HDAC inhibitors, 7,12-14 but their impact on ovarian cancer is less well defined. Here, we first evaluated the antitumor effects of entinostat in immunocompetent subcutaneous and intraperitoneal murine ovarian cancer models. In the subcutaneous model, entinostat led to a significant reduction in tumor growth compared with vehicle control by day 11 of treatment (19.9 ± 7.5 vs 32.9 ± 9.7 mm 2 ; P = .046), and this difference persisted at day 14 (19.0 ± 11.2 vs 35.0 ± 5.8 mm 2 ; P = .022) (Fig. 1A) . In the intraperitoneal model, entinostat led to a significant decrease in omental tumor weight compared with vehicle control after 14 days of treatment (44.7 vs 100.4 mg; P < .001). At the time mice were killed, only 1 of 5 mice treated with entinostat had visible ascites compared with 4 of 5 mice treated with vehicle control (Fig. 1B) .
A separate cohort of C57BL/6 mice (n = 5 per group) bearing intraperitoneal tumors was similarly treated with entinostat or vehicle control for 14 days and OS was measured (Fig. 1C) . Entinostat treatment led to a significant prolongation in median OS compared with vehicle control (74 vs 62 days; P = .005). The hazard ratio for death in the entinostat-treated mice was 0.26 (95% confidence interval, 0.06-1.21). These results indicate that daily entinostat treatment is able to significantly reduce ovarian tumor size and prolong survival in immunocompetent mice. 
Entinostat Induces Changes in mRNA Expression of Genes Important in Antitumor Immunity
It is estimated that HDAC inhibitors alter the expression of approximately 22% of genes, thereby broadly affecting tumor and immune cell phenotypes and collectively resulting in pleiotropic effects on the antitumor immune response. 20 To more comprehensively assess the effects of entinostat on the tumor-infiltrating immune response, we used the NanoString assay to evaluate expression of 46 genes predominantly related to adaptive immunity in RNA extracted from omental tumors of C57BL/6 mice (n = 5 per group) treated with entinostat or vehicle control. One mouse from each group had insufficient RNA quality for analysis and, as a result, was excluded from the final analysis, leaving 4 evaluable mice per group. Unsupervised hierarchical clustering revealed distinct gene expression patterns in omental tumors of mice treated with entinostat compared with vehicle control ( Fig. 2A) . When mean normalized expression values were compared, treatment with entinostat resulted in significant changes in mRNA expression in 21 of the 46 genes evaluated (Supporting Table 1 ). It is noteworthy that we observed increases in mean normalized expression of the effector T-cell-related molecules interferon gamma (IFNγ) (8.5 vs 2.9; P = .04), granzyme B (125.4 vs 9.5; P = .01), and C-X-C motif chemokine ligand 10 (CXCL10) (1636.4 vs 417.0; P = .02) (Fig. 2B) . The immune checkpoint molecule PD-L1 also was upregulated with entinostat treatment (mean normalized expression, 1090.6 vs 294.2 with control; P = .02) (Fig. 2C) , which was not unexpected, because it is positively regulated by IFNγ. 21 Expression of the immune-checkpoint molecules lymphocyte-activation gene 3 (LAG3) and B-lymphocyte and T-lymphocyte attenuator (BTLA) were significantly decreased with entinostat treatment (Fig. 2C) , whereas expression of PD1 and cytotoxic T-lymphocyte associated protein 4 (CTLA4) were unchanged (Supporting Table 1 ). Entinostat treatment also downregulated the expression of FoxP3, suggesting decreased immune suppression by regulatory T cells. Treatment with entinostat also resulted in significantly increased expression of all of the MHCI α chains as well as CIITA (mean normalized expression, 267.4 vs 132.1; P = .01); however, we did not observe a difference in the expression of I-A or I-E α or β chains at the mRNA level ( Fig. 2D and Supporting Table 1 ). These changes in gene expression suggest that entinostat alters the tumor microenvironment by upregulating antigen-presenting machinery as well as PD-L1 while also contributing to a more robust T-cell response.
Entinostat Increases MHCII Protein Expression on Omental Tumor Cells
Recently, we demonstrated that entinostat increased MHCII expression on ovarian cancer cells in vitro and in vivo using a spontaneously developing murine ovarian cancer model. 16 To extend those findings to our current model, we used flow cytometry to evaluate MHCII and PD-L1 expression in omental tumors of C57BL/6 mice treated with entinostat or vehicle control (n = 5 per group). Expression of the common leukocyte antigen CD45 was used to identify tumor-infiltrating immune cells, whereas cells that lacked CD45 expression were considered tumor or nonleukocytic stromal cells. This allowed a comparison of protein expression levels using (Fig. 3A) . There was a trend toward increased PD-L1 expression in the entinostat-treated mice; however, this was not statistically significant (MFI, 2832.0 vs 1593.0; P = .05) (Fig. 3B) . Thus, our results indicate that entinostat is able to induce surface expression of MHCII molecules in the syngeneic, intraperitoneal ID8 model of ovarian cancer.
Entinostat Increases the Frequency of CD8-Positive T Cells in Omental Tumors
Having demonstrated increased expression of MHCII on the surface of tumor cells in multiple ovarian cancer models as well as increased transcription of immune effector genes, we hypothesized that entinostat treatment would subsequently increase the frequencies of tumorinfiltrating lymphocytes. To test this hypothesis, omental tumors were harvested from C57BL/6 mice that were treated with either entinostat or vehicle control (n = 5 per group). Tumor-infiltrating lymphocytes were identified using flow cytometry, at first gating first on live, CD45-positive singlets followed by CD8-positive T cells, CD4-positive, or the regulatory T-cell markers CD25-positive/ FoxP3-positive cells (Fig. 4A) . Treatment with entinostat led to an increase in the frequency of CD8-positive T cells present in the tumor (21.0% vs 18.0%; P = .04). There were no differences in the frequencies of CD4-positive T cells (27.4% vs 29.4%; P = .25) or CD25-positive/FoxP3-positive regulatory T cells (4.7% vs 3.4%; P = .07) (Fig.  4B ). These data suggest that entinostat treatment leads to intratumoral accumulation of cytotoxic CD8-positive T cells while leaving CD4-positive and regulatory T-cell populations largely unaffected.
An Intact Immune System Is Required for the Antitumor Effects of Entinostat
Next, we evaluated the relative contributions of direct cytotoxic and cytostatic effects versus immune-mediated effects on tumor growth as well as MHCII and PD-L1 expression. Following the same protocol that we used for the C57BL/6 mice, Rag1 knockout mice, which lack T and B cells, were challenged intraperitoneally with ID8 tumors (n = 6 per group), then treated with either entinostat or vehicle control for 14 days, and subsequently killed. In these immunocompromised mice, there was a trending but nonsignificant reduction in omental tumor weight in the entinostat-treated mice compared with vehicle controls (54.3 vs 79.8 mg; P = .09), and 4 of 6 mice in each group had visible ascites at the time of tumor harvest (Fig. 5A ). This slight difference likely reflects the direct cytotoxic and cytostatic effects of entinostat on tumor cells. By flow cytometry, there was no difference in MHCII (MFI, 1250.0 vs 1483.0; P = .15) or PD-L1 surface expression (MFI, 805.8 vs 706.0; P = .26) on tumor cells in Rag1 knockout mice treated with entinostat compared with vehicle controls (Fig. 5B) . Again, cells that lacked CD45 expression were assumed to be tumor or nonleukocytic stromal cells. These data suggest that entinostat alone cannot induce MHCII expression on ID8 intraperitoneal tumors but, instead, requires adaptive immunity both to induce MHC II expression on CD45-negative cells and to control tumor outgrowth.
DISCUSSION
In this study, we demonstrate that the antitumor activity of the class I-specific HDAC inhibitor entinostat in a murine model of ovarian cancer depends on the drug's ability to enhance the adaptive immune response. In C57BL/6 mice with an intact immune system, treatment with entinostat resulted in significantly decreased tumor size and less ascites formation; however, in Rag1 knockout mice, which lack functional lymphocytes, these effects were lost. This suggests that the efficacy of entinostat in our syngeneic model is not caused entirely by direct cytotoxic or cytostatic effects of the drug but, rather, occurs predominantly through an indirect mechanism that involves stimulation of adaptive immunity. Entinostat treatment increased the percentages of CD8-positive T cells present in tumors and increased mRNA expression of IFNγ and granzyme B detected by NanoString analysis. This finding suggests that intratumoral, CD8-positive T cells are activated and exerting cytotoxic effector functions within the tumor microenvironment. Although the increase in mean normalized expression of IFNγ detected by NanoString analysis was relatively small, it may have been caused by the use of whole tumor lysate, wherein the T-cell transcripts are diluted simply by mass effect. Moreover, substantial increases in the IFNγ-inducible genes CXCL10, MHCI, CIITA, and PD-L1 support the notion that the observed increase in IFNγ expression is sufficient to drive significant downstream effects in the presence of entinostat. Indeed, it has been demonstrated that epigenetic modifying agents can prime IFNγ-responsive loci and potentiate transcription after receptor binding. 22, 23 There was no change in the frequency of total tumor-infiltrating, CD4-positive T cells or regulatory T cells by flow cytometry; however, both CD4 and FoxP3 expression levels were significantly decreased at the mRNA level (Supporting Table 1 ). Shen et al demonstrated a similar decrease in FoxP3 mRNA transcripts after entinostat treatment in prostate cancer, suggesting that findings in both models may reflect reduced T-regulatory cell suppressive function. 24 This idea will need to be confirmed in future studies.
Entinostat led to significant up-regulation of the MHCII pathway at both the mRNA and protein levels. Although NanoString analysis revealed no difference in mRNA expression of the I-A or I-E α or β chains with entinostat treatment, mRNA expression of the MHCII master regulator CIITA was significantly increased, and protein expression of MHCII was significantly upregulated, as demonstrated by flow cytometry. Although our prior in vitro data suggest that entinostat is able to upregulate MCHII expression directly on tumor cells, 16 we did not observe a similar increase in MHCII expression in the immunocompromised Rag1 knockout mice. This suggests that MHCII expression in vivo may be induced indirectly by IFNγ, which upregulates CIITA expression through the IFNγ-inducible pIV promoter (1 of the 4 potential IFNγ promoters), 25 or other immune effectors, in combination with entinostat. Although we did not evaluate the MHCI pathway at the protein level, mRNA expression of all MHCI pathway genes investigated was significantly increased with entinostat treatment. In addition, CIITA can contribute to MHCI expression by recruitment of the enhanceosome complex to site α and the SXY module 26 ; hence, we would expect that class I protein expression also would be upregulated in this model.
With entinostat treatment, PD-L1 expression was increased at the mRNA level, and there was a trend toward increased expression at the protein level. This observation is in agreement with Abiko et al, who noted that an increase in IFNγ expression in the tumor microenvironment can drive PD-L1 expression on tumor cells. Specifically, they observed that ovarian cancer tumor cells upregulate PD-L1 in response to IFNγ produced by cytotoxic T cells, leading to impaired effector functions, 21 termed adaptive resistance. 27, 28 In their study, this increased PD-L1 expression was associated with a poor prognosis, although PD-L1 also has been associated with increased cytotoxic T-cell Cancer December 15, 2018 infiltration and an improved prognosis in patients with ovarian cancer. 21, 29 These inconsistent results demonstrate the respective contributions of pre-existing antitumor immune responses as well as heterogeneity both within and between tumors in dictating outcome.
It is noteworthy that, in our observations, expression levels of canonical T-cell immune checkpoint molecules LAG3 and BTLA were decreased and PD-1 was unchanged at the mRNA level in whole tumor lysates after entinostat treatment. Signaling through multiple immune checkpoint molecules drives T-cell exhaustion, which permits tumor escape, 30 and expression profiles of these proteins are regulated largely by epigenetic modifications. 31, 32 It is encouraging to speculate that entinostat may be able to alter the progression of T-cell exhaustion in the tumor microenvironment for more durable antitumor immunity and better outcomes. 33 The immune effects of epigenetic agents were first studied in nonsmall cell lung cancer, when a group of patients who had been treated with the DNA methyltransferase inhibitor azacytidine subsequently received a checkpoint inhibitor; 60% of the treated patients achieved a durable clinical response. 34 In nonsmall cell lung cancer cell lines, azacytidine was induced expression of the MHCI pathway and PD-L1 as well as the expression of genes involved in several other important immune pathways. 35 In a diffuse B-cell lymphoma cell line, treatment with entinostat led to significantly increased MHCII expression through CIITA, 36 which is consistent with our findings of increased CIITA mRNA expression and increased MHCII protein expression. It is noteworthy that tumor MHCII expression led to enhanced immune responses in preclinical studies of breast cancer, renal cell carcinoma, prostate cancer, 37, 38 and (as demonstrated herein) ovarian cancer. Furthermore, these findings have been supported in clinical studies of patients with breast and ovarian cancer. In both disease sites, increased tumor cell MHCII expression strongly correlates with higher numbers of infiltrating cytotoxic T cells, which, in turn are associated with improved survival. 18, 19, 39 Several phase 1 and 2 clinical trials have investigated the use of HDAC inhibitors in ovarian cancer; however, the efficacy of these drugs appears limited when used as single agents or in combination with cytotoxic chemotherapy. 40, 41 Although our study was limited to 1 immunocompetent murine model and the sample sizes were small, our results suggest that treatment with entinostat leads to augmented adaptive effector functions and perhaps reduced T-cell exhaustion in ovarian cancer. Therefore, the most salient application of entinostat and other epigenetic modifiers may be in combination with other immune-potentiating modalities, like checkpoint inhibitors, to stimulate more durable antitumor immunity in women with ovarian cancer. These findings warrant further investigation in more diverse immunocompetent murine ovarian cancer models as well as patient-derived models.
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